
|Videos|December 17, 2021
Current developments in PSMA research
Author(s)Urology Times staff
“I believe we are getting to an era where we will be able to cure a significant subset of patients who we are not able to cure today,” says Neil H. Bander, MD.
Advertisement
In this video, Neil H. Bander, MD, shares his perspective on what the future of prostate-specific membrane antigen (PSMA) research will look like as well as what current developments are taking place. Bander is the Bernard & Josephine Chaus professor of urologic oncology at Weill Cornell Medicine, New York City, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












